" class="no-js "lang="en-US"> Life Line Screening Appoints Matt Miller as Chief Executive Officer
Monday, December 02, 2024

Life Line Screening Appoints Matt Miller as Chief Executive Officer

Life Line Screening, a leading mobile preventative health screening company, announces the appointment of Matt Miller to serve as Chief Executive Officer. This announcement comes as Life Line Screening is undergoing expansion of its product offering and customer services to better serve local communities across North America.

Mark Hanley, Chairman of Life Line Screening stated, “We are pleased to have Matt Miller join Life Line Screening as we enter into an exciting time of growth to better serve our customers with important information about their personal vascular health, stroke prevention, and more, and to continue to expand our relationships with our key business partners to deliver beneficial services.”

Matt brings a wealth of knowledge in technology, clinical drug development, and patient experience expertise from his experience at StudyKIK, where he was co-founder & CEO. StudyKIK is a leading Patient Recruitment & Technology Company which fundamentally streamlined the way people joined and participated in clinical trials around the world. The experience he brings to Life Line Screening will be paramount as the company undergoes expansion in services to provide the best possible preventative health experience for all its customers.

“I am focused on unlocking even more potential of Life Line Screening’s mission to provide lifesaving preventative health information to people through our innovative community screening events covering vascular health, stroke risk, metabolic disease understanding, and much more. I am honored to join such an innovative team as we work together to grow these important services through therapeutic expansion and technology,” said Matt Miller, CEO of Life Line Screening.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more